TOKYO - An experimental treatment from Shionogi & Co Ltd has shown rapid clearance of the virus that causes Covid-19, according to new data, the Japanese drug maker said on Sunday (April 24). The pill, S-217622, "demonstrated rapid clearance of the infectious SARS-CoV-2 virus", Shionogi said in a statement, citing Phase-2b results from the Phase II/III clinical trial of the.
An experimental treatment from Shionogi & Co. Ltd. has shown rapid clearance of the virus that causes COVID-19, according to new data, the Japanese drug maker said on Sunday.